1. Home
  2. BOBS vs IVA Comparison

BOBS vs IVA Comparison

Compare BOBS & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BOBS

Bob's Discount Furniture Inc. Common Stock

N/A

Current Price

$13.18

Market Cap

1.4B

ML Signal

N/A

Logo Inventiva S.A. American Depository Shares

IVA

Inventiva S.A. American Depository Shares

HOLD

Current Price

$4.25

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BOBS
IVA
Founded
1991
2011
Country
United States
France
Employees
N/A
77
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.1B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BOBS
IVA
Price
$13.18
$4.25
Analyst Decision
Buy
Strong Buy
Analyst Count
11
10
Target Price
$23.73
$16.20
AVG Volume (30 Days)
1.1M
466.4K
Earning Date
05-07-2026
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$12.58
N/A
Revenue Next Year
$7.43
$751.20
P/E Ratio
$18.67
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.74
$2.94
52 Week High
$23.11
$7.98

Technical Indicators

Market Signals
Indicator
BOBS
IVA
Relative Strength Index (RSI) 58.32 35.56
Support Level $9.97 $3.77
Resistance Level $13.57 $4.67
Average True Range (ATR) 0.74 0.32
MACD 0.15 -0.12
Stochastic Oscillator 77.61 24.46

Price Performance

Historical Comparison
BOBS
IVA

About BOBS Bob's Discount Furniture Inc. Common Stock

Bobs Discount Furniture Inc operates as a furniture retailer offering a wide variety of merchandise assortments across several categories, including upholstery, case goods, bedding, and other. The company generates the majority of its revenue from the sale of its products through its retail stores.

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

Share on Social Networks: